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with prevention of chronic disease and cancer over a one-year time horizon in the 
US. Age- and sex-specific population statistics, incidence, and mortality rates were 
used to model the prevalence and costs of chronic disease (Alzheimer’s, depres-
sion/suicide, diabetes, heart failure, Parkinson’s, stroke) and cancer (bladder, breast, 
colorectal, endometrial, esophageal, leukemia, liver, oral, pancreatic, prostate). 
Relative risks of chronic diseases and cancers by cups of coffee consumed daily 
were obtained from meta-analyses of prospective cohort and case-control studies. 
US daily coffee consumption, duration of disease, and attributable disease costs 
were obtained from the literature. The model was validated by comparing predicted 
disease-specific health care costs to estimates from published disease burden analy-
ses. Probabilistic sensitivity analysis (PSA) was conducted. Results: The model 
estimates that US coffee consumption prevents over 50,000 chronic disease and 
cancer deaths per year and results in an estimated health care savings of $33.4 bil-
lion per year (95% CI: $28.7bn, $38.3bn) of which $30.0bn is due to chronic disease 
and $3.4bn due to cancer. Cost savings were greatest for diabetes ($23.0bn), stroke 
($2.7bn), depression ($1.6bn), heart failure ($1.4bn), and Alzheimer’s disease ($1.1bn). 
In the PSA breast cancer and colorectal cancer were the only disease states in which 
the 95% CI ranged over no cost savings. ConClusions: This analysis suggests a 
potential public health benefit and health economic savings associated with cof-
fee consumption. Given the limitations of effectiveness data obtained from obser-
vational studies, additional research on the health effects of coffee is warranted.
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objeCtives: Few studies have examined excess health care costs among elderly 
breast cancer (BC) patients by receipt of human epidermal growth factor receptor 
2- (HER2-) targeted therapy. Methods: Women aged 65+ with an incident diagnosis 
of BC (index) and no history of other cancer were identified from 2006-2010 linked 
Surveillance, Epidemiology, and End Results (SEER) and Medicare data. Women were 
divided into two cohorts based on receipt of HER2-targeted therapy (trastuzumab 
or lapatinib) and matched 1:1 to non-cancer comparison cohorts by age, sex, and 
race. Continuous enrollment from 1 year pre-index (baseline) through disenroll-
ment, death, or the end of the data was required. All-cause costs were evaluated 
per-patient-per-month (PPPM) overall and by stage. Generalized linear models 
were constructed to identify factors associated with costs, by stage, controlling for 
demographics and comorbidity. Results: We identified 1,746 BC patients receiv-
ing and 35,114 not receiving HER2-targeted therapy. Unadjusted excess total costs 
(vs. non-cancer patients) were $4,079 PPPM for the HER2-targeted cohort and $990 
for the no HER2-targeted cohort (both P < 0.001), with larger differences at more 
advanced stages. Excess cost drivers were outpatient care and physician/provider 
services (including HER2-targeted therapy acquisition and administration costs). 
In multivariate analyses, Stage I HER2-targeted BC patients experienced 3.17 times 
greater total costs than non-cancer patients; while those with Stages II, III, and IV 
had 3.02, 3.40, and 4.27 times greater costs respectively (all P < 0.001). Similar trends 
with generally smaller magnitudes were observed among patients without HER2-
targeted therapy (0.48 [I]; 0.83 [II]; 1.67 [III]; 4.33 [IV]; all P < 0.001). Other significant 
cost predictors included older age, Black or Hispanic race, and baseline Charlson 
score> 2. ConClusions: Women with BC experience higher costs than non-cancer 
patients, with greater burden among those receiving HER2-targeted therapy. Excess 
cost drivers were outpatient care and physician/provider services.
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objeCtives: To compare costs associated with health care resource use in patients 
with advanced renal cell carcinoma (RCC) receiving first-line treatment with pazo-
panib versus sunitinib. Methods: COMPARZ was a multi-country, randomized, 
open-label, phase III study which demonstrated non-inferiority of pazopanib 
compared to sunitinib in adult patients with advanced RCC and no prior systemic 
therapy. Treatment continued until disease progression, unacceptable toxicity, with-
drawal of consent, or death. We estimated total costs by combining non-protocol 
health care resource use with standardized price weights from a US claims data-
base, and tracked from treatment initiation to study endpoint. Unadjusted and 
adjusted cost data were compared using univariate parametric (t-test) and non-
parametric (Kaplan Meier Sample Average [KMSA]) tests to account for skewness 
and right-censoring. We estimated 80% power to detect a difference of $8,000 in 
total costs (two-sided test), assuming α = 0.05. Additional analyses were performed 
to account for non-normal distribution of the data. Results: A total of 906 out of 
1,110 enrolled subjects (N= 454 pazopanib and N= 452 sunitinib) reported resource 
use data. Mean follow-up was 10.6 months. Both arms were balanced at baseline 
for clinical and demographic characteristics. The population was 73% male, mean 
age of 61 and good performance status (76% had Karnofsky score 90-100). Rates of 
emergency visits/hospital days, provider contacts, diagnostics, and procedures were 
greater for patients receiving sunitinib compared to pazopanib. Mean costs were 
$12,120 for pazopanib-treated patients and $15,727 for sunitinib-treated patients 
(p= 0.02), a difference of 29.7%. KMSA-derived costs were $21,026 for pazopanib and 
$29,043 for sunitinib. Cost differences between arms were significant when using 
Ordinary Least Squares and Generalized Linear Model approaches to adjust for 
of anastomotic leak following colorectal surgery was 6.4% (8,404 out of 131,689). 
After propensity score matching by key covariates, Patients with leak (vs. without 
leak) had higher in-hospital mortality (15.9% (95% CI: 15.2%, 16.7%) vs. 6.2% (95% CI: 
5.7%, 6.7%), p< 0.001), 30-day readmission rate (19.7% vs. 11.6%, p< 0.001), and post-
operative infection rate (19.3% vs. 4.5%, p< 0.001). The hospitalizations for patients 
with leak (vs. without leak) were more costly (£9,071±£4,588 vs. £6,420±£2,895, 
p< 0.001) and longer (20±23 vs. 11±13 days, p< 0.001). Anastomotic leak resulted in 
an additional cost of £2651 and an extra LOS of 9 days per patient. ConClusions: 
Our findings underscore the clinical/economic burden of anastomotic leak after 
colorectal surgeries in the UK. The presence of anastomotic leak was associated with 
greater mortality, LOS, and costs, highlighting the importance of providing prompt 
medical attention to minimize the impact of anastomotic leak.
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objeCtives: The aim of the analysis was understand the cost differences 
between the treatment with subcutaneous (SC) and intravenous (IV) bortezomib 
in patients with Multiple Myeloma treated by the Brazilian Private HealthCare 
System. Methods: A treatment cost model was developed to estimate and com-
pare the total costs for the treatments with SC and IV. The main inputs used in 
the model were: medication cost, adverse events cost, average number of cycles, 
infusion costs and total time of infusion. The model analyzed total costs from the 
perspective of payers (HMOs) and service provider (Infusion Clinic). Pharmaceutical 
unit costs were obtained from official government price list applying reimbursement 
inflators. Infusion time, dose, and number of cycles were obtained from published 
literature. Deterministic sensitivity analysis (DSA) was performed to assess robust-
ness of the model results. Results: The total infusion time per patient was 37.8 
minutes for SC and 75.4 minutes for IV. The medication factory price (MFP) was the 
same for both treatments with a reimbursement inflator of 15% in MFP. The Total 
Costs considering the HMO perspective were R$80,536.04 for SC and R$81,009.78 
for IV per patient. The comparison between the treatments generates a difference 
of -R$473.74. From the Infusion Clinic perspective the Total Costs were R$67,129.44 
for SC and R$67,881.02 for IV per patient. The total reimbursement (difference from 
income and cost) generated for the service provider was R$12,558.30 for IV and 
R$12,882.21 for SC per patient. The reimbursement comparison presented a financial 
return of R$323.91 per patient. In DSA, the SC formulation remained as the option 
associated with a lower economical impact for the HMO and a better financial return 
for the infusion clinic in all scenarios. ConClusions: The SC treatment compared 
with the IV treatment may generate saving for HMO and a rise of reimbursement 
for service provider.
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objeCtives: Multiple myeloma (MM) is the second most prevalent blood cancer in 
Canada. In patients who have undergone autologous stem cell transplant (ASCT); 
post-transplant maintenance therapy (MT) has been associated with substantial 
prolongation of progression-free survival. Consensus guidelines support the use of 
lenalidomide and bortezomib as post-transplant MTs, though these agents are sup-
ported by differing levels of clinical evidence. We sought to quantify and compare 
potential cost differences between two MTs, bortezomib and lenalidomide, in MM 
patients who have undergone ASCT. Methods: The total annual drug cost of the 
two MT options were calculated. Costs were based on 1.3 mg/m2 of bortezomib every 
two weeks, or 10 mg of lenalidomide daily. The cost of administration including 
oncology nursing time and pharmacist workload was added to the acquisition cost 
of bortezomib. Pharmacy costs including a 10% markup and dispensing fees were 
added to the acquisition cost of lenalidomide. Unit and labour costs were obtained 
from public Canadian sources. Additional analyses were conducted to consider the 
impact of several variables including the management of adverse events, treatment 
duration and alternate costing assumptions. Results: The total annual costs of 
treatment per patient were $32,560 and $144,976 for bortezomib and lenalidomide, 
respectively. The incremental differences were robust to changes in inputs and 
assumptions (to be presented in poster). ConClusions: In the absence of clear 
comparative clinical efficacy, the choice of MT may be influenced by patient char-
acteristics as well as patient and physician preference. Taken together, the results 
of this analysis suggest that when comparing MTs, bortezomib is much less costly 
than lenalidomide and therefore there are important cost differences that should 
also be considered.
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objeCtives: Over half of US adults consume coffee (Coffea arabica) on a daily basis. 
Epidemiologic studies suggest coffee may prevent some chronic diseases and can-
cers. This analysis aims to quantify the potential health economic impact of coffee 
consumption in the US. Methods: A period life-table analysis was developed to 
estimate the total direct health care cost savings of coffee consumption associated 
